+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Trends in Antiviral Drug Development. Edition No. 1. Trends in Drug Discovery

  • Book

  • 528 Pages
  • June 2025
  • John Wiley and Sons Ltd
  • ID: 6026903
Hard-to-find insights from industry professionals on success strategies for developing the next generation of antiviral blockbuster drugs

Presented by industry professionals with a track record of discovering new drugs and treatments, Trends in Antiviral Drug Development describes successful development efforts for antiviral compounds and therapies that have entered the market or are currently in clinical trials. Viruses are ordered by their target tissue, in line with contemporary drug development that focuses on tissue-targeted therapeutics. Other key trends in antiviral therapy, such as the effort to develop long-acting drugs, are described for each virus type, enabling readers to follow the current and future state in this core area of contemporary drug development.

Trends in Antiviral Drug Development includes discussion on: - Novel drugs against herpes viruses as well as the breakthrough drugs that cured HCV- siRNA therapeutics, a new antiviral modality, and the drug candidates that are progressing toward achieving an HBV cure- Drugs targeting viral entry, such as in HIV entry through attachment, co-receptor binding, and fusion- Novel therapeutics against tropical diseases such as dengue fever and monkey pox

Trends in Antiviral Drug Development is an essential read for medicinal chemists, pharmaceutical chemists, virologists, and all professionals seeking to understand new ideas and approaches to combat the ever-expanding universe of viral infections.

Table of Contents

Part I: HUMAN HERPES VIRUSES

Chapter 1: Letermovir/p>

Chapter 2: Pritelivir

Part II: HUMAN IMMUNODEFICIENCY VIRUS

Chapter 3: Dolutegravir

Chapter 4: Islatravir (EFdA)

Part III: HEPATITIS VIRUSES

Chapter 5: Imdusiran

Chapter 6: ARO-HBV/JNJ-3989

Chapter 7: Sofosbuvir

Chapter 8: Lidipasvir and Valpatasvir

Part IV: RESPIRATORY VIRUSES

Chapter 9: Presatovir

Chapter 10: Remdesivir

Chapter 11: Ensitrelvir

Chapter 12: VV-116

Chapter 13: Molnupiravir

Part V: TROPICAL DISEASE VIRUSES

Chapter 14: Mosnodenvir

Part VI: ORTHOPOXVIRUS

Chapter 15: Brincidofovir

Authors

Michael J. Sofia Arbutus Biopharma, Inc. Zhengqiang Wang University of Minnesota.